Antimicrobial resistance (AMR) is a significant public
health threat. The problem of AMR is growing, and yet few companies today are
actively working on developing new antibiotics.
After a century of research and development in infectious
diseases, our company knows there is no single or simple answer to the complex
problem of antimicrobial resistance. As the currently available antibiotics
become less effective because of AMR, millions of lives are threatened.
The need for new medicines that are effective against
multi-drug resistant bacteria is significant and urgent.
At MSD, we are committed to playing our part in the global
response to AMR — not only through investments in the development of new
vaccines and treatments for unmet medical needs, but also in our work to
support the appropriate use of these products around the world.
For over 80 years, our company has brought forward new
treatments each decade in every area of infectious disease and in multiple
modalities, including small molecules, vaccines and monoclonal antibodies.
MSD is determined to mobilize expertise and resources with
the goal of staying one step ahead of some of the world’s greatest killers. Our
company continues to push the boundaries of science with the hope and
expectation of inventing for the single greatest purpose – life.
We all have a responsibility to address this threat, and it
will take dedicated efforts from all sectors across health care, including
patients, to make a difference. We must put measures in place to ensure that we
have the antibiotics we need — today and in the future. The time to act is now.
